跳至主要内容
临床试验/NCT04697160
NCT04697160已完成不适用

An Observational Retrospective Cohort Study of Systemic Therapies for Relapsed or Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL), to Compare Outcomes to Those From Tafasitamab + Lenalidomide in the L-MIND Study

MorphoSys AG1 个研究点 分布在 1 个国家目标入组 3,573 人开始时间: 2020年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
MorphoSys AG
入组人数
3,573
试验地点
1
主要终点
Overall Survival (OS)

研究概览

简要总结

To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.

详细描述

This retrospective observational cohort study aims to generate a historical control consisting of R/R DLBCL patients who received currently guideline recommended therapies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Overall Survival (OS)

时间窗: through study completion, an average of 1 year

次要结局

  • Overall/Objective Response Rate (ORR)(through study completion, an average of 1 year)
  • Complete Response Rate (CR)(through study completion, an average of 1 year)
  • Duration of Response (DoR)(through study completion, an average of 1 year)
  • Event Free Survival (EFS)(through study completion, an average of 1 year)
  • Time to next treatment (TTNT)(through study completion, an average of 1 year)
  • Progression Free Survival (PFS)(through study completion, an average of 1 year)
  • Treatment discontinuation rate due to adverse events(through study completion, an average of 1 year)
  • Duration of treatment exposure(through study completion, an average of 1 year)

研究者

发起方
MorphoSys AG
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Observational Retrospective Cohort Study of Systemic... | 临床试验